Exact Sciences Total Assets 2006-2021 | EXAS

Exact Sciences total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Exact Sciences total assets for the quarter ending September 30, 2021 were $6.654B, a 52.82% increase year-over-year.
  • Exact Sciences total assets for 2020 were $4.925B, a 40.49% increase from 2019.
  • Exact Sciences total assets for 2019 were $3.506B, a 130.03% increase from 2018.
  • Exact Sciences total assets for 2018 were $1.524B, a 154.61% increase from 2017.
Exact Sciences Annual Total Assets
(Millions of US $)
2020 $4,925
2019 $3,506
2018 $1,524
2017 $599
2016 $377
2015 $364
2014 $313
2013 $147
2012 $112
2011 $97
2010 $97
2009 $26
2008 $6
2007 $15
2006 $24
2005 $38
Exact Sciences Quarterly Total Assets
(Millions of US $)
2021-09-30 $6,654
2021-06-30 $6,724
2021-03-31 $6,735
2020-12-31 $4,925
2020-09-30 $4,354
2020-06-30 $4,468
2020-03-31 $4,461
2019-12-31 $3,506
2019-09-30 $1,759
2019-06-30 $1,782
2019-03-31 $1,771
2018-12-31 $1,524
2018-09-30 $1,510
2018-06-30 $1,483
2018-03-31 $1,257
2017-12-31 $599
2017-09-30 $587
2017-06-30 $583
2017-03-31 $350
2016-12-31 $377
2016-09-30 $403
2016-06-30 $289
2016-03-31 $324
2015-12-31 $364
2015-09-30 $394
2015-06-30 $253
2015-03-31 $279
2014-12-31 $313
2014-09-30 $235
2014-06-30 $256
2014-03-31 $134
2013-12-31 $147
2013-09-30 $155
2013-06-30 $163
2013-03-31 $100
2012-12-31 $112
2012-09-30 $123
2012-06-30 $76
2012-03-31 $88
2011-12-31 $97
2011-09-30 $78
2011-06-30 $85
2011-03-31 $91
2010-12-31 $97
2010-09-30 $36
2010-06-30 $39
2010-03-31 $24
2009-12-31 $26
2009-09-30 $28
2009-06-30 $29
2009-03-31 $22
2008-12-31 $6
2008-09-30 $7
2008-06-30 $10
2008-03-31 $12
2007-12-31 $15
2007-09-30 $17
2007-06-30 $19
2007-03-31 $21
2006-12-31 $24
2006-09-30 $27
2006-06-30 $30
2006-03-31 $33
2005-12-31 $38
2005-09-30 $41
2005-06-30 $46
2005-03-31 $50
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $13.834B $1.491B
EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.969B 7.71
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.359B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $7.214B 0.00
Arcus Biosciences (RCUS) United States $3.030B 0.00
Emergent Biosolutions (EBS) United States $2.347B 8.44
ADC Therapeutics SA (ADCT) Switzerland $1.505B 0.00
Myovant Sciences (MYOV) United Kingdom $1.429B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.366B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09